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NMRMolecular dynamics simulations and NMR spectroscopy were used to compare the binding of two b-
blocker drugs to the chiral molecular micelle poly-(sodium undecyl-(L)-leucine-valine). The molecular
micelle is used as a chiral selector in capillary electrophoresis. This study is part of a larger effort to
understand the mechanism of chiral recognition in capillary electrophoresis by characterizing the molec-
ular micelle binding of chiral compounds with different geometries and charges. Propranolol and atenolol
were chosen because their structures are similar, but their chiral interactions with the molecular micelle
are different. Molecular dynamics simulations showed both propranolol enantiomers inserted their aro-
matic rings into the molecular micelle core and that (S)-propranolol associated more strongly with the
molecular micelle than (R)-propranolol. This difference was attributed to stronger molecular micelle
hydrogen bonding interactions experienced by (S)-propranolol. Atenolol enantiomers were found to bind
near the molecular micelle surface and to have similar molecular micelle binding free energies.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An ongoing challenge in separation science is the development
of techniques that can separate the enantiomers of chiral com-
pounds. These separations are especially important in the medical
and pharmaceutical ﬁelds because in a chiral in vivo environment,
a drug’s chirality often has a signiﬁcant impact on its biological
activity. For example, the b-blocker drug propranolol discussed
below is sold as a racemic mixture, however only the (S) enan-
tiomer has the desired b-blocking activity [1]. It is for this reason
that the Food and Drug Administration mandates that the proper-
ties of each enantiomer of a chiral drug be studied separately
before decisions are made to bring the drug to market as a single
enantiomer or as a racemic mixture [2]. In order to meet the grow-
ing need for effective and efﬁcient chiral separations, chiral forms
of high-performance liquid chromatography, gas chromatography,
thin layer chromatography, and supercritical ﬂuid chromatography
have been developed [3,4]. In each of these techniques,enantiomers are separated based upon differences in their free
energies of binding to the chiral stationary phase [5].
Chiral capillary electrophoresis (CE) was ﬁrst used by Gassman
et al., in 1985 to separate the enantiomers of dansyl amino acids
[6]. Subsequent work has shown that CE techniques often have
separation efﬁciencies up an order of magnitude higher than chiral
high-performance liquid chromatography [7]. In all chiral CE sepa-
rations, a racemic mixture and a chiral pseudostationary phase are
pulled down a capillary tube by an electric ﬁeld [8].
Pseudostationary phases employed in chiral CE separations include
chiral cyclodextrins, micelles, polymers, crown ethers, and proteins
[9]. Chiral separation in CE is accomplished when enantiomers
experience different free energies of binding to the chiral pseudo-
stationary phase. As a result the enantiomers move down the cap-
illary with different drift velocities and chiral separation is
achieved [7–9].
This investigation is part of an ongoing project aimed at charac-
terizing the mechanism of chiral recognition in CE separations
using chiral molecular micelles (MM) as the pseudostationary
phase. The long-term goal of the project is to combine what is
learned from Molecular Dynamics (MD) simulations with
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can be used to rationally select the best MM pseudostationary
phase for a given application. Molecular micelles were ﬁrst applied
to chiral CE separations by Wang and Warner and Dobashi et al., in
1994 [10–11]. A molecular micelle is a macromolecule containing
surfactant monomers connected by covalent bonds at the end of
each surfactant’s hydrocarbon chain. Wang and Warner used a
MM with chiral valine headgroups, while in the MM investigated
here, the headgroups were leucine-valine dipeptides [10].
Extensive work has been done using CE, NMR, and ﬂuorescence
anisotropy techniques to investigate the interactions between chi-
ral compounds and MM with both single amino acid and dipeptide
headgroups [11–29]. For example, CE measurements have been
used to study how the number and position of stereocenters in
the MM chiral headgroups and hydrophobic interactions between
headgroup and chiral analyte atoms affect chiral resolution [12–
17]. Hydrogen bonding and electrostatic interactions between
headgroup and analyte atoms have been investigated as well
[18–20]. Both NMR spectroscopy and CE have also been used to
identify the stereocenter in the MM headgroup that is the primary
site of chiral recognition [8,12,21,22]. Finally, ﬂuorescence aniso-
tropy and NMR measurements have been used to quantify the free
energies of MM binding for a number of chiral compounds [24–27].
The subject of this investigation was the MM poly-(sodium
undecyl-(L,L)-leucine-valine) (poly(SULV)). The molecule’s struc-
ture is shown in Fig. 1(a). Earlier work with poly(SULV) showed
that it was a both an effective and versatile chiral selector
[14,28]. Successful chiral CE separations using poly(SULV) were
ﬁrst reported by Billiot et al., who showed this MM provided supe-
rior enantioseparation of chiral binapthyl compounds compared to
dipeptide-terminated MMwith VV, LL, or VL headgroups [14]. Also,
in a comprehensive investigation of CE separations of 75 chiral
compounds, Shamsi et al. showed that poly(SULV) was able to suc-
cessfully separate the enantiomers in over 75% of the racemic mix-
tures investigated [28]. Molecular dynamics (MD) simulations of
poly(SULV) in aqueous solution have also been reported [29,30].
These experiments showed that the poly(SULV) headgroups were
conformationally ﬂexible and adopted a relatively open conforma-
tion giving water molecules and chiral ligands access to the chiral(a) 
(b)
(d)
Fig. 1. (a) Poly(SULV), (b) Propranolol, (c) Atenolol, and (d) 1,1’-binaphthyl-2,2-diyl hy
literature NMR results and in the hydrogen bond analyses.centers of the dipeptide headgroups [29,30]. Overall, previous
work with poly(SULV) suggests that the MM is an effective chiral
selector because it contains multiple chiral centers on the dipep-
tide headgroup and the non-polar amino acids in the headgroup
interact both hydrophilicly and hydrophobicly with chiral analytes.
The ﬂexible poly(SULV) headgroup conformation also provides sol-
vent and chiral ligands with a high degree of access to the molec-
ular micelle’s chiral centers [14,28–30].
MD simulations have also been used to investigate the binding
of the enantiomers of the chiral compound 1,1’-binaphthyl-2,2’-
diyl hydrogen phosphate (BNP) to poly(SULV) [31]. The chemical
structure of BNP is shown in Fig. 1(d). The results obtained in this
study were as follows. First, four unique poly(SULV) binding sites
or binding pockets were identiﬁed. Either (R) or (S)-BNP were then
individually docked into each of these pockets and MD simulations
were carried out. Calculation of the BNP enantiomers’ free energies
of binding to the MMwere then used to identify each enantiomer’s
preferred binding site. (S)-BNP was found to have a more negative
or more favorable MM binding free energy than the corresponding
(R) enantiomer. This observation was consistent with CE experi-
ments, where in separations of racemic BNP mixtures, (R)-BNP
eluted before (S)-BNP. NMR diffusion experiments also showed
that (S)-BNP binds more favorably to the MM than the (R) enan-
tiomer. Finally, the MD simulations showed that the (S)-BNP inter-
actions with poly(SULV) were stronger than the (R) enantiomer in
part because in the preferred binding pocket, (S)-BNP penetrated
deeper into the hydrophobic MM core. Also, the (S)-BNP oxygen
atoms formed hydrogen bonds with the MM headgroup to a
greater degree than the (R) enantiomer [31].
Here we report an MD simulation study of propranolol and ate-
nolol binding to poly(SULV). The chemical structures of these com-
pounds are shown in Fig. 1(b) and (c). Both atenolol and
propranolol belong to a class of drugs known as b-blockers. b-
blockers hinder the effects of adrenaline and lessen the force with
which the heart contracts. They are also used to treat ocular hyper-
tension because they reduce the pressure in the eye by modulating
the rate of liquid production. b-blockers are, therefore, prescribed
to treat conditions including heart arrhythmia, glaucoma,
migraines, and anxiety [32].(c)
drogen phosphate (BNP) molecular structures. Atom labels are used to reference
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order to gain further insight into the mechanism of chiral recogni-
tion in CE separations with molecular micelles. Although propra-
nolol and atenolol have similar chemical structures, their chiral
interactions with poly(SULV) have been found to be quite different.
For example, the Shamsi et al., study discussed above showed pro-
pranolol was one of eighteen analytes experiencing strong chiral
interactions with poly(SULV) [28]. Chiral compounds in this cate-
gory were separated with high resolution using relatively low
MM concentrations. In contrast, atenolol was in a class of twenty
compounds with weak chiral interactions with the MM. These
compounds required high concentrations of poly(SULV) to achieve
baseline resolution of the enantiomers [28]. Therefore, the inter-
molecular interactions between poly(SULV) and atenolol/propra-
nolol were compared to identify key factors affecting chiral
recognition in CE. Finally, both b-blockers have chiral centers
instead of a chiral plane and many more potential hydrogen bond
donor/acceptor atoms than BNP. Therefore, their interactions with
poly(SULV) were also investigated to complement previous MD
simulation work.
2. Materials and methods
2.1. Materials
(R)-(+)-atenolol and (S)-(-)-atenolol (99%) were purchased from
Sigma–Aldrich, Inc. and were used as received. Sigma–Aldrich also
provided 99.9 atom %D deuterium chloride and 99% atom %D deu-
terium oxide. The MM poly(SULV) was graciously provided by the
laboratory of Professor Isiah Warner. The molecular micelle was
synthesized by a method described previously [10]. Solutions used
in the NMR diffusion analyses were prepared gravimetrically and
contained 5.0 mM of either (R) or (S)-atenolol and a 25.0 mM
equivalent monomer concentration of poly(SULV) in a solvent mix-
ture of 90% H2O and 10% D2O. The pH of the solution was adjusted
to 6.5 by adding small aliquots of DCl(aq). The solutions were
allowed to equilibrate for at least an hour at 25.0 C before NMR
analysis.
2.2. NMR experiments
NMR diffusion coefﬁcient measurements were done at 25.0 C
on a Bruker 300 MHz DPX spectrometer with an actively shielded
z-gradient coil. The gradient coil produced a maximum gradient
strength of 50.3 G cm1. The bipolar pulse pair encode–decode
pulse sequence was used for the diffusion coefﬁcient measure-
ments [33]. For each trial, twelve NMR spectra were collected with
magnetic ﬁeld gradient strengths, G, ranging from 2.5 to
30.2 G cm1. At each gradient value, the gradient pulse duration,
d, was 4.0 ms, the short delay between the bipolar gradients, s,
was 0.20 ms, and the diffusion time D was 250.0 ms. The H2O peak
was removed from each spectrum by presaturation for 2.0 s during
the relaxation delay. The spectral width in all NMR spectra was
6173 Hz. Three replicate trials were performed with each sample.
After data collection, each FID was apodized with 1.0 Hz line
broadening, Fourier transformed, and baseline corrected. The
intensities of the aromatic resonances at 7.18 and 6.90 ppm and
the poly(SULV) methylene chain resonance at 1.2 ppm were then
recorded at each gradient strength. Plots were prepared of the nat-
ural log of the peak intensity versus the quantity
(c  G  d)2  (Dd/3) where c is the magnetogyric ratio, d is the mag-
netic ﬁeld gradient duration, and D is the diffusion time. This anal-
ysis resulted in linear plots with a slope of –D, where D is the
atenolol or poly(SULV) diffusion coefﬁcient. Linear regression anal-
yses were used to extract the diffusion coefﬁcients. The R2 values
for all linear ﬁts were greater than 0.99.2.3. MD simulations
Computational studies of complexes containing either propra-
nolol or atenolol enantiomers and poly(SULV) were carried out
with molecular modeling and MD simulation protocols used suc-
cessfully in prior studies [29–31]. These methods are summarized
as follows. Intermolecular complexes containing either propranolol
or atenolol and poly(SULV) were generated using the MOE soft-
ware package (MOE 2011.10) [34]. The initial MM structure used
for atenolol or propranolol docking was a representative structure
with respect to the average structure from a 15 ns MD simulation
containing only the molecular micelle [31]. This representative
structure was generated in the following manner. First the average
structure over all the structures from an MD simulation containing
only poly(SULV) was calculated. This average structure was not
used for docking, though, because it was only a mathematical aver-
age and there was no guarantee that it had structural features that
were reasonable and representative of the real molecular micelle.
Therefore, the Root Mean Squared Deviation (RMSD) of each MD
simulation structure with respect to the average was calculated.
The representative structure used for ligand docking had the low-
est RMSD with respect to the average. This lowest RMSD structure
was the real structure from the MD simulation that was most sim-
ilar to the average structure. In other words, when a ligand mole-
cule binds to poly(SULV), the representative structure chosen for
docking represented a reasonable and likely structure/conforma-
tion of the MM that the ligand will encounter.
It should also be noted that previous MD simulation work
showed that the poly(SULV) headgroups were conformationally
ﬂexible [29]. Initial ligand docking was performed, though with a
static, representative MM structure chosen by the method
described above. However, during the MD simulations with the
intermolecular complexes there were no restraints placed upon
the structure or ﬂexibility of the MM. The headgroups were instead
free to explore all possible conformations. Therefore, headgroup
ﬂexibility was taken into account during the MD simulations. The
initial MM structure used for ligand docking and the MM: ligand
complexes generated during the docking procedure were likely,
reasonable, and representative structures that served as a starting
point for the subsequent MD simulations.
In the ﬁrst step of the ligand docking procedure, atenolol and
propranolol enantiomers were built and energy minimized in
MOE. The MM ligand binding pockets were then identiﬁed with
the Site Finder module of MOE. The Site Finder module utilized
alpha-sphere and discrete-ﬂow methods developed by
Edelsbrunner and Mucke and Edelsbrunner and Shah [35,36]. An
alpha sphere is deﬁned as a dummy atom contacting four receptor
atoms on its boundary. There are no atoms inside the alpha sphere.
The alpha sphere method was used to probe receptor zones of tight
atom packing available for ligand docking. Each alpha sphere
placed in the receptor was classiﬁed as either ‘‘hydrophilic’’ or ‘‘hy-
drophobic’’ depending upon whether the sphere was in a good or a
poor hydrogen-bonding environment within the receptor. During
binding pocket identiﬁcation, no restrictions were placed on the
total number of binding sites identiﬁed. After binding site identiﬁ-
cation, the Site Finder module scored and visualized individual
binding pockets by populating them with alpha spheres and then
ranking them with respect to the number of hydrophobic receptor
atoms in contact with retained alpha spheres.
Next, either the (R) or (S) enantiomer of propranolol or atenolol
were separately docked into each binding site using the standard
docking protocol implemented in MOE 2011.10 [34]. During the
docking procedure, the MM was set as the receptor and was struc-
turally rigid, while the propranolol or atenolol ligands were set as
completely ﬂexible. MOE used the London dG scoring function to
score each of the docking poses [37]. Of the hundreds of docked
Table 2
Free energies of poly(SULV) binding and fractional pocket populations for propranolol
and atenolol enantiomers in each MM pocket. Fractional populations were calculated
with Eq. (2).
Binding pocket Binding free energy (kJ mol1) Fractional population
(S)-Propranolol
Pocket one 71.09 1.0
Pocket two 9.63 1.67  1011
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were saved by the MOE software and constructed for future study.
The best scoring structures for each of the separate binding sites
were then used in the subsequent MD simulation studies [37]. It
should be noted that there was a high degree of structural similar-
ity among the top-scoring docking structures from the MOE anal-
ysis. Therefore, it would be expected that during the MD
simulations, the MM: ligand complexes would explore structures
corresponding to all of the thirty top-scoring poses. The best scor-
ing MM: ligand complex was thus used as the starting point for
each of the MD simulations because it represented a likely, reason-
able, and representative structure for the intermolecular complex.
Again no constraints were placed on the size of the binding
pockets, therefore if a pocket was small compared to the size of
the propranolol or atenolol molecules, the ligands were free move
in the selected pocket or to move into adjacent or nearby MM bind-
ing sites to form low free energy ligand: molecular micelle inter-
molecular complexes. Pockets one, ﬁve, and six were in the same
general region of the MM but not in the exactly same location.
However, the docking analyzes showed that the best scoring, i.e.
lowest free energy, poses from analyzes where propranolol or ate-
nolol were initially docked into pockets one, ﬁve, and six all placed
the ligands in the same area of the molecular micelle. For example,
when the lowest free energy intermolecular complexes generated
by initially docking (S)-propranolol into pockets one and ﬁve were
examined, the distance between the respective propranolol ether
oxygen atoms was 2.1 Å. Likewise, when complexes generated
after docking (S)-propranolol into pockets one and six were exam-
ined, the distance between the respective propranolol ether oxy-
gen atoms was 0.9 Å. These distances were small compared to
the size of the propranolol molecule. Analogous results were
obtained when the same analysis was done with (R)-propranolol
and the atenolol enantiomers. Therefore, these distance measure-
ments suggest that the best scoring structures from the docking
analyses performed with MM pockets one, ﬁve, and six all placed
the ligands in the same region of the molecular micelle. In other
words, before docking molecular micelle pockets one, ﬁve, and
six were not in the exact same location, but after the propra-
nolol/atenolol docking analyses ligands initially docked into those
pockets were all placed in the same region of the molecular micelle
to form complexes with low binding free energies.
Below the MM monomer chains nearest the docked ligands in
each binding pocket (Table 1) and the free energies of MM binding
for the atenolol and propranolol enantiomers (Table 2) are pre-
sented. These data also suggest that the intermolecular complexes
resulting from analyses where the ligands were initially docked inTable 1
Poly(SULV) chains nearest to the docked propranolol and atenolol molecules in each
MM binding pocket. Nearest chains were the same for the two enantiomers of both
ligands.
Ligand binding pocket MM chains closest to the docked ligand
Propranolol
Pocket one 2, 9, and 15
Pocket two 6, 13, and 18
Pocket three 7, 10, and 11
Pocket four 3, 4, and 6
Pocket ﬁve 2, 9, and 15
Pocket six 2, 9, and 15
Atenolol
Pocket one 2, 9, and 12
Pocket two 6, 13, and 18
Pocket three 7, 11, and 17
Pocket four 3, 4, and 6
Pocket ﬁve 2, 9, and 12
Pocket six 2, 9, and 12pockets one, ﬁve, and six all placed the ligands in the same region
of the molecular micelle. Therefore, it was concluded that a single
MD simulation could be used to represent propranolol or atenolol
binding to the MM in this region of the MM receptor.
MD simulations with each of the different intermolecular com-
plexes containing either atenolol or propranolol and poly(SULV)
were performed using AMBER12 and the parm99 force ﬁeld
[38,39]. Each MD simulation contained poly(SULV), either the (R)
or (S) enantiomer of atenolol or propranolol, twenty Na+ ions,
and from 8360 to 8689 TIP3P water residues. The MM had a charge
of 20, with each monomer chain contributing 1 to the overall
charge. The 20 MM charge was balanced by twenty Na+(aq) counte-
rions. The propranolol and atenolol ligands had a charge of +1
because in the capillary electrophoresis separations reported in the
literature, both b-blockers were cationic [28]. Before MD simulations
were performed, the complexes were energy minimized. A 20 ps MD
simulation was used to heat the system to 300 K and a one ns sim-
ulation was carried out to equilibrate the system to one atmosphere
and 300 K. These equilibration steps were followed by a 15.0 ns pro-
duction run to collect statistical data. In the production run, the time
step was 2.0 fs, structures were saved every 0.2 ps, and cubic peri-
odic boundary conditions (PBC) were employed. The cutoff used in
the PBC was set so that the edge lengths were well above twice
the cutoff distance for the van der Waals interactions (10 Å) [40].
Finally, the MD simulation trajectories were analyzed using the ptraj
and cpptraj utilities in AMBER 12 [38]. In the hydrogen bond analy-
ses, the distance cutoff was set at 3.5 Å between the heavy atoms
participating in the H-bond. The angle cutoff between the donor
and acceptor atoms was ±30 [38].
The mm-PBSA method was used to calculate the MM binding
free energies reported below [41]. These values represent the dif-
ference between the mm-PBSA free energy of the atenolol or pro-
pranolol: MM intermolecular complex and the sum of the
individual free energies of the (R) or (S) ligand and the MM recep-
tor. This calculation is illustrated in Eq. (1), where
G = Gsolute + Gsolvent.Pocket three 9.21 n/a
Pocket four 8.38 1.01  1011
Pocket ﬁve 36.79
pocket six 34.94
(R)-Propranolol
Pocket one 38.28 1.0
Pocket two 13.55 4.60  105
Pocket three 1.74 3.89  107
Pocket four 16.49 n/a
Pocket ﬁve 16.45
Pocket six 15.59
(S)-Atenolol
Pocket one 16.73 0.73
Pocket two 16.41 n/a
pocket three 9.42 n/a
Pocket four 14.37 0.27
Pocket ﬁve 16.53
Pocket six 10.64
(R)-Atenolol
Pocket one 21.31 0.58
Pocket two 3.63 4.61  104
Pocket three 20.51 0.42
Pocket ﬁve 19.16
Pocket six 10.03
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The above Gsolute term is given by Gsolute = E  T  S, where S is
the entropy contribution to ligand binding and E is the MM energy
averaged over the MD simulation. The entropy contribution was
approximated with AMBER12 using a rigid rotor model in which
the vibrational frequencies were calculated using the quasi-har-
monic approximation [42]. With this approximation, the eigenval-
ues of the mass-weighted covariance matrix constructed from
every member of the ensemble were approximated as frequencies
of global, orthogonal motions [42]. The energy term included con-
tributions from the electrostatic and van der Waals interactions for
the complex, receptor, and ligand. The free energy calculations
were performed in AMBER12 with a non-bonded cutoff of 99 Å
[38]. The above Gsolvent term is given by Gsolvent = Ges + Gnes, where
Ges is the electrostatic contribution calculated with the PB method,
and Gnes is the non-electrostatic contribution. The later value is
proportional to the solvent-accessible surface area of the molecule.3. Results and discussion
Propranolol and atenolol structures are shown in
Fig. 1(a) and (b), respectively. The compounds have the same chiral
side chain, but differ in their hydrophobic characteristics.
Propranolol contains two fused aromatic rings, while atenolol con-
tains a single aromatic ring and an amide group para to the chiral
side chain. Mohsen-Nia et al., recently reported that propranolol
had a larger n-octanol/water partition coefﬁcient than atenolol
[43]. The authors concluded that propranolol was, therefore, over-
all more hydrophobic than atenolol because this partition coefﬁ-
cient is the accepted physiochemical quantity used to assess the
hydrophobicity of pharmaceutical compounds [43]. Differences in
the two b-blocker structures and hydrophobicities also likely inﬂu-
ence their interactions with poly(SULV). For example, the more
hydrophobic propranolol molecule would be expected to place its
aromatic rings in the molecular micelle’s hydrocarbon core, while
the less hydrophobic atenolol molecule would be expected to bind
in a more hydrophilic environment nearer the MM surface.
NMR NOESY experiments reported in 2006 showed that propra-
nolol does in fact bind to poly(SULV) by inserting its aromatic rings
ring into the MM hydrophobic core [21]. NOESY is a two-dimen-
sional NMR experiment in which cross peaks are detected between
the NMR resonances of atoms that are within 5 Å of one another
[44]. This technique has been used in a number of studies to inves-
tigate the spatial relationships between MM and bound ligand
atoms [8,21,22,45]. In an NMR study of the association of ﬁve chiral
ligands with poly(SULV), NOESY cross peaks were detected
between the propranolol ring resonances and resonances from
the poly(SULV) hydrocarbon chain protons. Furthermore, reso-
nances from protons labeled H4–H8 in Fig. 1(b) showed more
intense NOESY cross peaks with the MM hydrocarbon chain reso-
nances than propranolol protons labeled H2 and H3. This result
suggested that when bound to poly(SULV), propranolol protons
H4–H8 point toward the MM core and protons H2 and H3 point
away from the core and toward the micelle surface [21].
In the NOESY spectra, however, resonances from the propra-
nolol chiral side chain protons were overlapped by MM peaks.
Therefore, the spatial relationships between the propranolol side
chain protons and those of the MM dipeptide headgroup could
not be investigated and a detailed model of propranolol:
poly(SULV) binding could not be developed [21]. The MD simula-
tion study reported here provided a more complete picture of pro-
pranolol: poly(SULV) interactions and allowed differences between
propranolol and atenolol association with the MM to be investi-
gated. In the MD simulation results presented below, MM binding
pockets were ﬁrst identiﬁed and distance measurements wereused to conﬁrm that the enantiomers remained bound to the
MM when docked into each pocket. Next, binding free energies
were calculated and used to identify each ligand’s preferred MM
binding site. Solvent accessible surface area (SASA) calculations
were then used to investigate the degree of ring insertion into
the poly(SULV) hydrocarbon core and, ﬁnally hydrogen bond anal-
yses were used to investigate how the (R) and (S) enantiomers of
each ligand interacted differently with the MM.
3.1. Distance measurements
In a previous study of BNP binding to poly(SULV), the MOE soft-
ware package was used to identify six binding sites or pockets on
the MM where ligand binding could occur [31]. An analogous pro-
cedure was employed here, with MOE being used to identify bind-
ing pockets and then to individually dock either (R) or (S)-atenolol
or (R) or (S)-propranolol into each of these MM pockets. It should
be noted that pocket identiﬁcation was done with the MM receptor
before ligand docking, so the BNP and atenolol/propranolol pockets
into which the ligands were docked were initially the same [31].
The poly(SULV) MM contained twenty covalently bound surfac-
tant monomer chains which were labeled sequentially one through
twenty. In 2002, Billiot et al., used ﬂuorescence quenching experi-
ments to measure the aggregation numbers of ﬁfteen MM contain-
ing dipeptide headgroups [18]. It was found that poly(SULV) had an
aggregation number in the range of 18–23 monomer chains per
molecular micelle. Therefore, the structures constructed for the
MD simulations contained twenty surfactant monomers. Using
the above numbering scheme, Table 1 shows the surfactant chains
that were nearest to the ligand enantiomers in each of the initial
docked structures. The nearest chains in Table 1 were the same
for (R) and (S)-atenolol and for (R) and (S)-propranolol. The nearest
MM chains were also found to be the same for propranolol and ate-
nolol enantiomers in pockets two and four. In pocket three, the
propranolol enantiomers were nearest MM chains seven, ten, and
eleven while the atenolol enantiomers were nearest MM chains
seven, eleven, and seventeen.
Furthermore, Table 1 also shows that in the intermolecular
complexes generated when propranolol was initially docked into
MM pockets one, ﬁve, and six, the ligand enantiomers contact
the same MM monomer chains (two, nine, and ﬁfteen). Likewise,
the atenolol molecules initially docked in these same three pockets
(one, ﬁve, and six) are also nearest the same MM monomer chains
(two, nine, and twelve). These results further suggest that during
the docking procedure ligands initially docked in pockets one, ﬁve
and six were all placed in the sameMM binding site. The MM bind-
ing free energy results presented in Table 2 show that the (R) and
(S) enantiomers of both atenolol and propranolol had lower free
energies of binding when the ligands were initially docked in
pocket one. Therefore, this complex was selected as the structure
best representing ligand association in the pocket one/ﬁve/six
region of the MM. The docked structures presented in Fig. 2 and
the distance versus simulation time plots presented in
Supplemental Information Figure 1, therefore, show pocket one
results and omit results for pockets ﬁve and six.
Fig. 2(a) shows the structure of poly(SULV) before ligand dock-
ing with binding pocket number one highlighted. Fig. 2(b) shows
an analogous structure highlighting pockets two, three, and four.
In Fig. 2(a) and (b) a surface is used to outline the pockets. On
the surface, the lipophilic portions of the pockets are green and
the hydrophilic portions are purple. The pockets are also populated
with alpha-spheres. White and red alpha spheres correspond to
hydrophobic and hydrophilic regions. Below the spatial arrange-
ment of these regions will be used to rationalize why propranolol
and atenolol associate with poly(SULV) by binding to pocket one.
Fig. 2(c) and (d) show initial poly(SULV) structures with (S)-
(c) (d)
(e) (f)
(a) (b)
Pocket 3 
Pocket 2 
Pocket 4 
Pocket 1 
Fig. 2. (a) Poly(SULV) binding pocket one from the MOE analysis. The pocket is populated with alpha spheres and lipophilic and hydrophilic pocket regions are green and
purple, respectively. (b) Poly(SULV) pockets two, three, and four from the MOE analysis. (c) (S)-atenolol docked into poly(SULV) binding pockets. Molecules in pockets one,
two three, and four are red, green, blue, and purple, respectively. (d) An alternate view of the structure in (c) showing the location of pocket one. (e) (S)-propranolol docked
into poly(SULV) pockets one through four. Coloring scheme is the same as (c). (f) An alternate view of (e) showing pocket one.
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show analogous structures for (S)-propranolol. The structures in
Fig. 2(c)–(f) conﬁrm that the four pockets place the ligands at dif-
ferent locations on the MM. Finally, it should be noted that
although Fig. 2 shows (S)-atenolol or (S)-propranolol in the four
pockets of the same MM, the MD simulations contained the MM
and only one ligand enantiomer.
The distances between the propranolol/atenolol ether oxygens
(labeled O1 in Fig. 1) and the center of the MM were monitored
during the MD simulation. The center of the MM was taken as
the ﬁrst carbon atom in the hydrocarbon chain of surfactant chain
number ten. Fig. 1(e) in the Supplemental Information shows a
poly(SULV) structure with this atom highlighted. In a previous
study, these measurements were used to assess whether the
ligands remained associated with the MM throughout the MD sim-
ulation [31]. Previous work also showed that poly(SULV) had an
elliptical shape with radii for major and minor axes of 23 and
11 Å, respectively [29]. Therefore, in the propranolol and atenolol
MD simulations, if the separation between the ligand and the cen-
ter of the MM was comparable to or less than these radii and the
separation was also relatively constant, the ligand likely remained
associated with the MM. In contrast, if the distance increased to a
value much larger than the poly(SULV) radii, this result would sug-
gest that the ligand moved away from the MM and into the bulk
water phase. Finally, it should be noted that these distance mea-
surements only provide a way to assess whether the ligands stay
close to the MM or drift into the bulk water. They do not provideinformation about whether the ligands remain in the original pock-
ets into which they were docked [31].
Distance vs. simulation time plots for (S) and (R)-propranolol,
are shown in Supplemental Information Fig. 1(a) and (b), respec-
tively. Both propranolol enantiomers remained at a relatively
stable distance from the MM core in each MD simulation. For
example, after 2.0 ns, the (S)-propranolol molecules in all four
pockets remained within 20 Å of the MM core. Likewise, after
5 ns, (R)-propranolol showed similar behavior. It can, therefore,
be concluded that neither (R) nor (S)-propranolol drifted away
from the MM and into free solution during the MD simulations.
The (S)-atenolol distance vs. simulation time plot in
Supplemental Information Fig. 1(c) shows similar behavior. In
pocket four, the ligand began 25 Å from the center of the MM
and moved closer to the core as the MD simulation proceeded.
The (S)-atenolol ligands in pockets one through three also
remained within 15 Å of the center of the MM and the distances
changed very little over the course of the MD simulation.
Therefore, like (S) and (R) propranolol, it can be concluded that
(S)-atenolol does not drift away from the MM during any of the
MD simulations. In the (R)-atenolol analyses, however, the ligand
remained associated with the MM in pockets one through three,
but drifted away into free solution when docked into pocket four.
This conclusion is supported by the large separation between the
ligand and the MM core shown in Supplemental Information
Fig. 1(d). Also, a structure extracted from the MD simulation at
10.0 ns is shown in Supplemental Information Fig. 2. This structure
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into the bulk water phase. Therefore, the results of the (R)-ateno-
lol: pocket four simulation will not be considered further.3.2. Free energy calculations
After identifying the pockets in which the propranolol and ate-
nolol enantiomers remained associated with the MM, the binding
free energies for the enantiomers in each MM pocket were calcu-
lated to identify the preferred enantiomer binding site(s). In this
context, free energy of binding is the difference between the com-
plex’s free energy and the sum of the free energies of the
poly(SULV) receptor and atenolol or propranolol ligand. The bind-
ing free energies and associated fractional populations of each MM
pocket are presented in Table 2. The fractional populations were
calculated from the binding free energies with the Boltzmann rela-
tion in Eq. (2).
f i ¼
eGi=kB :TP
ieGi=kB :T
ð2Þ
Gi is the binding free energy of the ith pocket, kB is Boltzmann’s con-
stant, T is temperature, and the summation goes over the binding
sites of the MM. Since as discussed below, pockets one, ﬁve, and
six were collapsed into a single binding site (pocket one) fractional
populations were not calculated for pockets ﬁve and six. Fractional
populations were also not calculated for pockets with positive Gi
values.
The Table 1 results suggested that during the docking proce-
dure, ligands initially docked into pockets one, ﬁve, and six were
placed in the same region of the molecular micelle to form com-
plexes with low free energies. The free energies of binding reported
in Table 2 support this conclusion. Table 2 shows that the (R) and
(S)-propranolol pockets one, ﬁve, and six binding free energies are
all lower than the binding free energies of propranolol in pockets
two-four. Therefore, after the docking procedure, propranolol
enantiomers initially located in pockets one, ﬁve and six were all
placed in the same region of the molecular micelle where ligand
binding was energetically favorable. The (S)-propranolol pocket
ﬁve and six binding free energies of, respectively 36.79 and
34.94 kJ mol1, however, were higher than the pocket one value
of 71.09 kJ mol1. Therefore, the intermolecular complex in
which the ligand was initially docked in pocket one had the overall
lowest Gi and was taken as the structure best representing (S)-pro-
pranolol binding in this low free energy region of the MM. An anal-
ogous conclusion can be drawn from the (R)-propranolol binding
free energies. The pocket one, ﬁve and six binding free energies
of, respectively 38.28,16.45 and 15.59 kJ mol1 were all lower
than pockets two-four. However, of the three (one, ﬁve, and six)
pocket one had the lowest Gi value. Therefore, again the inter-
molecular complex in which (R)-propranolol was initially docked
in pocket one was taken as the complex best representing enan-
tiomer binding in this region of the MM.
The propranolol binding free energy analyses also showed that
as with BNP, each propranolol enantiomer preferentially associ-
ated with one of the poly(SULV) pockets [31]. For example, the
(S)-propranolol binding free energy of 71.09 kJ mol1 in pocket
one is much lower than those of poly(SULV) pockets two-four.
The fractional population of this binding site is in turn near one.
Likewise, the binding free energy of 38.28 kJ mol1 for (R)-pro-
pranolol in pocket one is also much lower or more favorable than
the other MM binding sites. Again, the (R)-propranolol fractional
population for pocket one is near one. The propranolol results are
similar to BNP, in that one MM pocket is preferred for both ligands.
It should be noted, though that the BNP enantiomers preferred MM
pocket two, while the propranolol enantiomers preferred pocketone [31]. Given the differences between the BNP and propranolol
structures and the fact that the former molecule has a chiral plane
and the latter has a chiral atom, preference for different MM bind-
ing pockets is not unexpected. Finally, since the binding free
energy analyses showed MM-bound (R) and (S)-propranolol enan-
tiomers both predominately occupied pocket one, the analyses
presented below will focus on comparing the intermolecular inter-
actions experienced by the propranolol enantiomers in this pocket.
Table 2 also shows that the pocket one MM binding free energy
calculated for (S)-propranolol was considerably lower than that of
(R)-propranolol. Shamsi et al., reported that propranolol experi-
enced strong chiral interactions with poly(SULV) [28]. This exper-
imental result is consistent with the large difference in binding
free energies observed in the MD simulations. Furthermore, the
MD simulation free energy calculations showed that (S)-propra-
nolol interacts more favorably with poly(SULV) than the (R) enan-
tiomer. This result is consistent with both CE and NMR
experiments. A CE study by Valle et al., showed that when propra-
nolol enantiomers were separated using poly(SULV) as the chiral
selector, the (S) enantiomer eluted after the (R) enantiomer, indi-
cating that (S)-propranolol bound to the MM more strongly than
(R)-propranolol during the CE separation [8]. Furthermore, in an
NMR study of chiral analyte interactions with poly(SULV), NMR
diffusion experiments analogous to those presented below for ate-
nolol were used to measure each propranolol enantiomers’ associ-
ation constant with poly(SULV). The results of this study showed
that (R) and (S)-propranolol had respective poly(SULV) association
constants of 993 ± 52 and 2191 ± 26 M1 [21]. The lower free
energy of binding calculated for (S)-propranolol in the MD simula-
tions is consistent with the larger association constant measured
with NMR spectroscopy.
Finally, the structures shown in Fig. 2(a) and (b) can be used to
rationalize why pocket one is the preferred propranolol MM bind-
ing site. Pocket one of the MM is shown in Fig. 2(a). Note that the
pocket contains a lipophilic or hydrophobic region depicted by the
green surface and white alpha-spheres. This region extends into
the MM hydrocarbon core. Binding pocket one also contains a sub-
stantial hydrophilic portion depicted by the purple surface and red
alpha spheres. Similarly, Fig. 1(b) shows that propranolol contains
nonpolar fused rings at one end of the molecule attached to a chiral
side chain containing all of the molecule’s hydrogen bond donor
and acceptor atoms. Therefore, it seems likely that propranolol
preferentially binds to pocket one because the orientations of the
hydrophobic and hydrophilic regions of the pocket match that of
the propranolol ligand. In other words, the shape of pocket one
could allow propranolol to insert its hydrophobic aromatic rings
into the MM core and then place its more polar chiral side chain
near the pocket’s hydrophilic surface where hydrogen bonds
between the ligand and MM atoms could form. Fig. 2(b) shows
MM pockets two through four. These pockets also contain both
lipophilic and hydrophilic regions, however of the four pockets dis-
played, pocket one has the largest number of red or hydrophilic
alpha spheres. Therefore, pocket one would in turn likely provide
the atoms on propranolol’s chiral side chain with the largest num-
ber of potential hydrogen bonding sites. The MD simulation analy-
ses presented below will be used to show that propranolol does
associate with the MM in this manner.
Table 2 also presents poly(SULV) binding free energies and frac-
tional populations for (R) and (S)-atenolol. Table 1 shows that
when both (R) and (S)-atenolol were initially docked into MM
pockets one, ﬁve, and six the enantiomers were near the same
MM monomer chains. The free energy results in Table 2 show that
(S)-atenolol in pocket one had a lower free energy of MM binding
(16.73 kJ mol1) than pockets ﬁve (16.53 kJ mol1) or six
(10.64 kJ mol1). Therefore, the intermolecular complex gener-
ated by initially docking (S)-atenolol in pocket one was selected
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Fig. 3. NMR diffusion plot for atenolol enantiomers. The slope of each line is D.
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pocket one/ﬁve/six region of the MM. An analogous conclusion
can be drawn from the Table 2 (R)-atenolol: poly(SULV) binding
free energies.
The binding free energy results in Table 2 also show that (S)-
atenolol associates with MM pockets one and four with respective
fractional populations of 0.73 and 0.27. (R)-atenolol also associates
with two pockets (one and three) with respective fractional popu-
lations of 0.58 and 0.42. Therefore, unlike propranolol and BNP, the
atenolol enantiomers do not show a strong preference for a single
poly(SULV) binding site [31]. The atenolol binding free energies are
also substantially less negative than the respective propranolol val-
ues, indicating that the more polar atenolol molecule associates
overall less strongly with the MM than the more hydrophobic
propranolol.
Since the atenolol enantiomers associate with multiple
poly(SULV) pockets, Eq. (3) was used to calculate a pocket-
averaged free energy of binding, G.
G ¼
X
i
f i  Gi ð3Þ
In Eq. (3), Gi and fi are, respectively the free energy of binding
and fractional population of the ith pocket. For (S)-atenolol only
pockets one and four with negative free energies of binding were
included in the summation. The result of this analysis was that
the pocket-averaged free energies of binding for (R)-atenolol and
(S)-atenolol were, respectively 20.97 and 16.09 kJ mol1.
Therefore, unlike propranolol where the (S) enantiomer had a
much more negative binding free energy than the (R) enantiomer,
the MM binding free energies for the two atenolol enantiomers
were similar. This result is consistent with the Shamsi et al., ﬁnding
that atenolol had weak chiral interactions with poly(SULV) and
that high MM concentrations were necessary to achieve resolution
of the atenolol enantiomers [28].
Finally, as with propranolol, Fig. 2(a) and (b) can be used to
rationalize why the atenolol enantiomers preferentially bind to
MM pocket one. In these ﬁgures, the purple parts of the surfaces
and the red alpha spheres both depict hydrophilic regions. As dis-
cussed above, Mohsen-Nia et al., showed that atenolol was overall
more hydrophilic than propranolol [43]. Therefore, it seems likely
that the hydrophilic atenolol enantiomers would bind preferen-
tially to the MM pocket providing the largest number of potential
hydrophilic and hydrogen bonding interactions. Fig. 2(a) and (b)
show that of the four pockets displayed, pocket one contains the
largest number of red or hydrophilic alpha spheres. In addition, if
atenolol interacted primarily with the purple or hydrophilic region
of pocket one, the enantiomers would be placed near the surface of
the MM. The MD simulation analyses presented below show that
the atenolol enantiomers associate with poly(SULV) in this
manner.
3.3. NMR diffusion experiments
While NMR spectroscopy has been used to investigate propra-
nolol association with poly(SULV) [21], to our knowledge NMR
studies have not examined atenolol binding to this MM.
Therefore, in order to provide another point of comparison
between the MD simulations and experiment, NMR diffusion stud-
ies were done to measure the association constants for each ateno-
lol enantiomer binding to poly(SULV). In these experiments, pulsed
ﬁeld gradient NMR was used to measure the diffusion coefﬁcients
of either (R) or (S)-atenolol in a mixture containing the drug and
poly(SULV). The NMR experiments were done at pH 6.5 where
the Shamsi et al., study reported atenolol was in cationic form
[28]. In the diffusion measurements, a series of NMR spectra were
collected as described above with increasing magnetic ﬁeldgradient strength, G. A representative diffusion plot for (R) and
(S) atenolol in solutions containing poly(SULV) is shown in Fig. 3.
The slopes of the lines in Fig. 3 are –D, where D is the atenolol
enantiomer diffusion coefﬁcient. In the diffusion experiments, it
can be assumed that the atenolol enantiomer diffusion coefﬁcient,
Dobs, is the weighted average of the free solution, Dfree, and MM-
bound (Db) values [21,22,46]. The MM-bound diffusion coefﬁcient
was taken as the diffusion coefﬁcient of poly(SULV). This relation-
ship is shown in Eq. (4), with fb representing the mole fraction of
bound atenolol molecules and Dfree representing the free solution
atenolol diffusion coefﬁcient, (5.17 ± 0.06)  1010 m2 s1.
Dobs ¼ Db  f b þ ð1 f bÞ  Dfree ð4Þ
After fb was calculated, Eq. (5) was used to calculate the atenolol:
poly(SULV) association constant, K [21].
K ¼ f bð1 f bÞ  ½SULV 
ð5Þ
In Eq. (5), [SULV] is the poly(SULV) equivalent monomer concentra-
tion of 25.0 mM.
Diffusion coefﬁcients, fb values, and association constants from
the NMR analyses are presented in Table 3. These measurements
showed that (S)-atenolol had a poly(SULV) association constant
of 12.8 ± 1.2 M1 and (R)-atenolol had a K value of 13.0 ± 1.4 M1.
Therefore, the MD simulation results are consistent with the
NMR measurements in that the simulations show the two enan-
tiomers have similar binding free energies, while the NMR experi-
ments show that the enantiomers have almost identical MM
association constants. Both results are also consistent with the
CE observation that atenolol has weak chiral interactions with
poly(SULV). Hydrogen bonding and solvent accessible surface area
results from the MD simulations will now be presented in order to
further explore the structures of the intermolecular complexes
formed by poly(SULV) and the propranolol and atenolol
enantiomers.
3.4. Solvent accessible surface areas
In order to assess the depth of penetration of the propranolol and
atenolol enantiomers into the coreof theMM, solvent accessible sur-
face areas (SASA) for each enantiomerweremonitored as a function
of simulation time. The SASA analyseswere also used to determine if
the MD simulations were consistent with the literature NOESY
results presented above which showed propranolol bound to
poly(SULV) by inserting its aromatic rings into theMMhydrocarbon
core [21]. Fig. 4(a) compares the SASA for (R) and (S) propranolol in
pocket 1 of poly(SULV). The top curve in Fig. 4(a) shows the SASA for
(S)-propranolol during an MD simulation that included only the
Table 3
Dobs, Db, fb, and poly(SULV) association constants for atenolol enantiomers.
(R)-atenolol (S)-atenolol
Dobs (m2 s1) (4.60 ± 0.05)  1010 (4.61 ± 0.03)  1010
Db (m2 s1) (1.19 ± 0.01)  1010 (1.19 ± 0.01)  1010
fb 0.244 ± 0.018 0.242 ± 0.015
K (M1) 13.0 ± 1.4 12.8 ± 1.2
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binding pocket, the SASA for both enantiomers were considerably
less than the free solution value, indicating thatMMbinding shields
a signiﬁcant fraction of both propranolol enantiomers from solvent
exposure. Fig. 4(a) also shows that for the ﬁrst seven ns of the MD
simulation, (R) and (S) propranolol SASA values were nearly identi-
cal, indicating that the enantiomers were in a similar molecular
environment. From seven to thirteen ns, the (S)-propranolol SASA
increased slightly with respect to the (R) value. The SASA of the
two enantiomers were again similar near the end of theMD simula-
tion. Therefore, both propranolol enantiomers have SASA’s approx-
imately 200 Å2 less than the free solution value when bound to
poly(SULV) pocket one and the (S) enantiomer spends part of the
MD simulation in a slightlymore solvent exposed environment than
the (R) enantiomer.
In addition, the SASA of the atoms making up the enantiomers’
aromatic rings and separately the atoms in the chiral side chain
were compared to their respective free solution values. The results
of these analyses are shown in Fig. 5(a) for (S)-propranolol and
Fig. 5(b) for the (R) enantiomer. Fig. 5(a) shows that in moving
from free solution into pocket one, the SASA of the atoms making
up the (S)-propranolol aromatic rings decreased by 86% from an
average value of 184 Å2 to 27 Å2. The SASA of the atoms in the
molecule’s chiral side chain, however decreased only 65% from
an average value of 233 Å2 in free solution to a MM-bound average
value of 83 Å2. Similar results were obtained for (R)-propranolol
with the SASA of the ring atoms decreasing 80% (184–37 Å2) and
the corresponding chiral side chain values decreasing 59% (233–
97 Å2). Therefore, for both (R) and (S)-propranolol, the aromatic
ring atoms experienced a greater percentage decrease in their
SASA upon association with the MM when compared to the atoms
in the chiral side chain. This result suggests that when bound to the
MM in pocket one, both enantiomers insert their aromatic rings
into the molecular micelle’s hydrocarbon core, thus causing the
large decrease in ring SASA observed in Fig. 5. The side chain atoms
in contrast are less shielded from the solvent and are, therefore,
likely nearer the surface of the MM.
Fig. 6 shows structures extracted from the MD simulations at
representative time steps of 7.2 ns for (S)-propranolol (Fig. 6(a))0
100
200
300
400
500
0 3 6 9 12 15
SA
SA
 (Å
2 )
simulation time (ns)
Free Solution (S)-Propranolol 1
(R)-Propranolol 1
(a) (b
Fig. 4. Solvent accessible surface area versus simulation time plots for (a) (R) and (S)-pro
in pockets one and three.and 13.8 ns for (R)-propranolol (Fig. 6(b)). The Fig. 6 structures
were generated with the MOE software used for ligand docking
[34]. In the extracted structures, the binding pocket is displayed
as a surface with green and red representing, respectively
hydrophobic and hydrophillic regions, respectively. Overall the
extracted structures show that both propranolol enantiomers are
bound to the MM with their aromatic rings inserted into the
hydrocarbon core and their chiral side chains pointing toward
the MM surface. Also, given the spatial proximity of the propra-
nolol ring and MM hydrocarbon chain protons in these structures,
it would be expected that in an NMR NOESY experiment, cross
peaks would be detected between these protons. This was the
experimental result obtained in the literature NOESY analysis dis-
cussed above [21]. Furthermore, the yellow dotted lines in
Fig. 6(a) and (b) represent arene-H hydrophobic interactions
detected by the MOE software between the propranolol aromatic
rings and MM hydrocarbon chain atoms [34]. The detection of
these hydrophobic interactions in the extracted structures for both
enantiomers conﬁrms that favorable hydrophobic interactions
occur in both structures between the propranolol and MM core.
The blue dotted lines in Fig. 6 represent hydrogen bonds detected
by the MOE software [34]. H-bond formation between the ligands
and MM is discussed in more detail below.
Finally, it should be noted that in our previous MD simulation
study of BNP binding to poly(SULV), both BNP enantiomers bound
preferentially to pocket two, however, in this pocket (S)-BNP had a
much lower SASA and thus penetrated more deeply into the MM
core, while (R)-BNP had a higher SASA and thus remained nearer
the MM surface [31]. The behavior for the propranolol enantiomers
is different, with both enantiomers placing their aromatic rings
into the MM core and chiral side chains near the surface. In other
words, unlike BNP, (S)-propranolol’s more favorable MM binding
free energy is likely not caused by its ability to move deeper in
the MM core than the (R) enantiomer.
Atenolol SASA plots for the (S) enantiomer in pockets one and
four and the (R) enantiomer in pockets one and three, i.e. the pock-
ets with the highest fractional occupancies, are shown in Fig. 4(b).
When compared to the propranolol plot in Fig. 4(a), the atenolol
enantiomers were found to have consistently larger SASA’s. This
result indicated that the atenolol enantiomers do not penetrate
into the micelle core as deeply as propranolol. As discussed above,
this result is expected given the more polar nature of the atenolol
molecule. Fig. 4(b) also shows that the SASA values for the atenolol
enantiomers in the pockets shown are all very similar to one
another. When average and standard deviations of the SASA values
were calculated for each pocket, SASA values of 253 ± 37 Å2 for (S)-
atenolol pocket one, 221 ± 41 Å2 for (S)-atenolol pocket four,
262 ± 48 Å2 for (R)-atenolol pocket one, and 229 ± 34 Å2 for (R)-0
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Fig. 5. (a) Plots of the solvent accessible surface areas of the (S)-propranolol aromatic ring and chiral side chain atoms in free solution and in poly(SULV) pocket one. (b) Plots
analogous to (a) for (R)-propranolol. (c) Plots of the solvent accessible surface areas of the (S)-atenolol aromatic ring and chiral side chain atoms in free solution and in
poly(SULV) pocket one. (d) Plots analogous to (a) for (R)-atenolol. (e) Plots of the solvent accessible surface areas of the (S)-atenolol aromatic ring and chiral side chain atoms
in free solution and in poly(SULV) pocket four. (f) Plots analogous to (e) for (R)-atenolol in pocket three.
(a) (S)-propranolol (b) (R)-propranolol 
Fig. 6. (a) (S)-Propranolol pocket one structure extracted from the MD simulation at 7.2 ns. (b) (R)-Propranolol-pocket one structure extracted from the MD simulation at
13.8 ns. Structures are displayed in MOE. In the pocket map green corresponds to a hydrophobic region and red to a hydrophillic region.
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different at the 95% conﬁdence level. Therefore, even though the
atenolol enantiomers occupied different regions on the MM when
docked into pockets one, three, and four, the MD simulations sug-
gested that the intermolecular interactions experienced by the
enantiomers in these pockets were very similar. This conclusion
can be drawn from a comparison of both the binding free energies
in Table 2 and the average SASA values. Therefore, when the ateno-
lol enantiomers encounter the MM, they can both bind to one of
two relatively low energy pockets with both pockets placing the
ligand near the surface of the MM.
As with propranolol, separate SASA’s for the atoms making up
the atenolol enantiomers’ aromatic ring and chiral side chain were
compared to their respective free solution values. Fig. 5(c) and (d)
show plots of these SASA’s versus simulation time in pocket one for
(S)-atenolol and (R)-atenolol, respectively. Analogous plots for (S)-
atenolol in pocket four and (R)-atenolol in pocket three are shown
in Fig. 5(e) and (f). Compared to propranolol, smaller decreases
were observed in the atenolol ring and side chain SASA’s when
moving from free solution into the MM-bound state. For example,
in (S)-atenolol, the SASA of the ring atoms decreased 57% (91 –
39 Å2) and the SASA of the chiral side chain atoms decreased 44%
(244–138 Å2) in moving from free solution into MM pocket one.
Similar decreases (58% and 38%) were observed for (R)-atenolol
in pocket one and for (S)-atenolol (63% and 43%) and (R)-atenolol
(69% and 51%) in pockets three and four, respectively. In propra-
nolol, however, the respective decreases were 85% and 65%.
Therefore, the SASA analyses showed that as expected atenolol
binds to poly(SULV) near the MM surface where its atoms are less
shielded from solvent exposure than observed with propranolol,
whose aromatic rings were inserted into the MM hydrocarbon
core.Table 4
Molecular micelle: propranolol enantiomer hydrogen bonds formed in the pocket one
MD simulations.
Acceptor atom Donor atom Percent occupancy
(S)-Propranolol pocket one
MM chain 9: ACO2 (S)-propranolol NH2+ 74.80
MM chain 9: ACO2 (S)-propranolol OH 46.46
(S)-propranolol AOH MM chain 9: Val NH 30.90
MM chain 18: ACO2 (S)-propranolol NH2+ 28.34
MM chain 18: ACO2 (S)-propranolol OH 22.98
(S)-propranolol AOH MM Chain 9: Leu NH 18.48
MM chain 9: ACO2 (S)-propranolol OH 15.83
MM chain 9: ACO2 (S)-propranolol NH2+ 11.94
MM chain 12: Leu C@O (S)-propranolol NH2+ 11.28
(R)-Propranolol pocket one
(R)-propranolol AOH MM chain 2: Val NH 19.53
(R)-propranolol AOH MM chain 2: Leu NH 4.11
(R)-propranolol O1 MM chain 2: Leu NH 2.313.5. Hydrogen bond analysis
The SASA analyses suggested that both propranolol enan-
tiomers inserted their aromatic rings into the MM hydrocarbon
core, while atenolol enantiomers bound nearer to the MM surface.
Hydrogen bond formation between solvent molecules and both the
atenolol/propranolol ligands and MM dipeptide headgroups were
investigated in order to provide additional evidence for this associ-
ation model. Table 1 in the Supplemental Information gives the
total number of H-bonds formed between water molecules and
MM chains two, nine, and ﬁfteen during the MD simulations in
which either (R) or (S)-propranolol was docked into poly(SULV)
pocket one. Recall from Table 1, MM chains two, nine, and ﬁfteen
were the poly(SULV) chains closest to the enantiomers in this
pocket. The total H-bonds formed by each individual chain and
the solvent H-bonds with the highest percent occupancies are
listed in the table as well. This analysis showed that 2396 H-bonds
formed between the solvent and nearest MM chains in the (R)-pro-
pranolol MD simulation and 2703 H-bonds formed in the corre-
sponding (S)-propranolol MD simulation. All of the hydrogen
bonds detected, though, had occupancies less than two percent.
This result indicates that water molecules were present in the
binding pockets during the MD simulations and that they formed
H-bonds with the MM dipeptide headgroups. All these hydrogen
bonds, however, were relatively transient and short-lived in nature
and no water molecules formed H-bonds with poly(SULV) head-
group atoms that persisted for a signiﬁcant fraction of the MD sim-
ulation. Table 1 in the Supplemental Information also gives
analogous solvent: poly(SULV) hydrogen bond results for the near-
est MM chains from the (S)-atenolol pocket one and pocket four
and the (R)-atenolol pocket one and pocket three MD simulations.
As with propranolol, many H-bonds formed between the MMchains and water, but all H-bonds detected had occupancies less
than ten percent.
Supplemental Table 2 gives the total number of H-bonds
detected between solvent molecules and donor/acceptor atoms of
the atenolol and propranolol enantiomers. (R) and (S)-propranolol
were found to form 88 and 94 H-bonds with solvent molecules
during their respective MD simulations. If both enantiomers bound
to the MM in a similar fashion by inserting their rings into the MM
core, they would be expected to form a comparable number of H-
bonds with solvent. This was the result obtained in the solvent
hydrogen bond analyses. Supplemental Table 2 also gives the total
number of hydrogen bonds detected between solvent molecules
and the atenolol enantiomers. In the atenolol analyses, many more
solvent H-bonds were detected when compared to propranolol. For
example, in the pocket one MD simulation, (R) and (S) atenolol
formed, respectively 8778 and 822 H-bonds with water, compared
to less than 100 solvent H-bonds formed by the propranolol enan-
tiomers. The large number of intermolecular-solvent hydrogen
bonds observed during the atenolol MD simulations suggests that
when atenolol’s enantiomers bind to poly(SULV) they remain near
the MM surface where their solvent exposure is high.
While both the SASA and solvent hydrogen bond analyses show
that the propranolol enantiomers bind to the MM with their aro-
matic rings inserted into the MM hydrocarbon core, these analyses
do not provide insight into why, as shown by the binding free
energy calculations, (S)-propranolol interacts more favorably with
poly(SULV) than (R)-propranolol. Therefore, the hydrogen bonds
formed between the propranolol enantiomers and the MM dipep-
tide headgroup were also investigated. These results are presented
in Table 4. It is these intermolecular H-bonds that offer insight into
the stronger MM interactions experienced by (S)-propranolol.
The Table 4 results show that in pocket one, (S)-propranolol
experienced considerably more hydrogen-bonding interactions
with the MM than the (R) enantiomer. In Table 4, the intermolec-
ular (S)-propranolol: MM H-bonds with percent occupancies
greater than 10% are listed. (R)-propranolol showed fewer H-bond-
ing interactions, so instead the interactions with the three highest
percent occupancies are shown. Table 4 shows that a H-bond
between an (S)-propranolol NH2+ donor atom and an acceptor atom
on the valine carboxylate group of MM chain nine was resident for
74.80% of the MD simulation. A second H-bond between different
atoms on the same two MM and ligand functional groups had an
occupancy of 11.94%. In addition, a H-bond with an occupancy of
28.34% formed between the (S)-propranolol NH2+ group and the
valine carboxylate group of chain 18. Other high occupancy H-
bonds involving the (S)-propranolol hydroxyl group also formed.
One of these hydrogen bonds had an occupancy of 46.46% and
formed between an (S)-propranolol OH donor and a valine
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between a ligand OH donor atom and a different valine CO2 oxygen
atom had an occupancy of 15.83%. Finally, in the (S)-propranolol
MD simulation, H-bonds were also detected between the ligand
OH group and amide NH donor atoms of the MM dipeptide head-
group. For example, a H-bond with a 30.90 % occupancy formed
between the (S)-propranolol hydroxide oxygen atom and a valine
NH donor on MM chain nine and another H-bond with an occu-
pancy of 18.48% formed between the ligand OH oxygen and the
MM chain nine leucine NH.
The relatively large number of high percent occupancy hydro-
gen bonds formed between (S)-propranolol and MM chain nine
atoms suggests that multiple hydrogen bonds likely form simulta-
neously between the (S) enantiomer and MM atoms. To test this
hypothesis, the distances between the heavy atoms making up
the three highest occupancy H-bonds detected in the (S)-propra-
nolol: MM pocket one MD simulation were measured. Recall the
heavy atom distance cutoff for H-bonds used in the AMBER12 anal-
yses was 3.5 Å. Therefore, if multiple donor and acceptor atoms are
simultaneously separated by a distance of less than 3.5 Å, it is
likely that multiple H-bonds are formed. Fig. 3 in the
Supplemental Information shows the distances between the heavy
atoms making up the three (S)-propranolol: MM chain 9 hydrogen
bonds with the highest percent occupancies. The distances are gen-
erally larger and more variable in the ﬁrst four ns of the MD sim-
ulation. After four ns though, all three distances remain both
relatively constant and at or below the 3.5 Å distance cutoff for
H-bond formation. An analysis of the Supplemental Information
Fig. 3(a) results showed that for 84% of the MD simulation two
or more of the distances plotted were less than 3.5 Å. Therefore,
it can be concluded that for a signiﬁcant portion of the MD simu-
lation (S)-propranolol H-bond donor/acceptor atoms in the OH
and NH2+ functional groups are sufﬁciently close to MM
donor/acceptor atoms to allow multiple intermolecular hydrogen
bonds to form.
Fig. 3(b) in the Supplemental Information plots the distances
between the heavy atoms in the (R)-propranolol: poly(SULV)
hydrogen bonds with the three highest percent occupancies.
Early in the MD simulation, the (R)-propranolol distances show
greater variability than those of the (S) enantiomer. After approx-
imately six ns, the three (R) enantiomer distances remain relatively
constant, but they are still larger and more variable than the (S)
enantiomer distances in Supplemental Information Fig. 3(a).
Furthermore, an analysis of the Supplemental Information
Fig. 3(b) data showed that two or more of the H-bond distances(S)-propranolol 
poly(SULV) chain 9 
74.8% 
46.5% 
30.9% 
(R)-
(a)  (b
Fig. 7. (a) Structure showing (S)-propranolol and poly(SULV) chain nine extracted from t
chain two extracted from the MD simulation at 7.96 ns.plotted were simultaneously within 3.5 Å for only 6.5% of the MD
simulation. Therefore, the lower H-bond percent occupancies and
the generally larger distances between the ligand: MM
donor/acceptor atoms suggest that during the (R)-propranolol
pocket one MD simulation, two or more intermolecular hydrogen
bonds seldom form.
In order to further compare hydrogen bond formation between
the propranolol enantiomers and poly(SULV), structures were
extracted from the MD simulations at 7.41 and 7.96 ns for (S)-pro-
pranolol and (R)-propranolol, respectively. These time steps where
chosen because they were near the middle of the MD simulation
when both the (R) and (S)-propranolol distances plotted in
Supplemental Information Fig. 3 were relatively constant.
Hydrogen-bonded structures for (S)-propranolol and MM chain
nine and for (R)-propranolol and MM chain two are shown in
Fig. 7(a) and (b), respectively. The (S)-propranolol structure in
Fig. 7(a) shows that when the 74.8% occupancy H-bond forms
between the ligand amine and MM carboxylate groups, the (S)-
propranolol hydroxide moiety is placed at a location allowing
two additional H-bonds with occupancies of 46.5% and 30.9% to
form. The 46.5% occupancy H-bond is between the (S)-propranolol
OH hydrogen atom and a valine carboxylate oxygen and the 30.9%
occupancy H-bond formed is between a ligand OH acceptor and the
MM valine NH donor. Note that these same three hydrogen bonds
were also detected by the MOE software in the structure shown in
Fig. 6(a).
In contrast, the (R)-propranolol structure in Fig. 7(b) shows that
when the highest occupancy hydrogen bond forms between the
ligand hydroxide and valine NH groups (19.5%), the other
donor/acceptor atoms on both the ligand and MM are too far apart
to form additional H-bonds. Additional images from other time-
steps of the MD simulations showing analogous behavior for both
propranolol enantiomers are shown in Supplemental Fig. 4.
Therefore, (S)-propranolol likely interacts with poly(SULV) more
strongly than the (R) enantiomer, as shown by the MD simulation
free energy calculations and CE and NMR experiments [8,21], in
part because the (S) enantiomer forms multiple high percent occu-
pancy hydrogen bonds with the MM dipeptide headgroup atoms,
while the (R) enantiomer does not.
The hydrogen bonds detected in the atenolol: poly(SULV) MD
simulations are shown in Table 5. Only H-bond results for the
pockets with the lowest free energies of MM binding (one and four
for (S)-atenolol and one and three for (R)-atenolol) are shown.
When compared to the propranolol hydrogen bond analyses, the
atenolol enantiomers were found to form more hydrogen bonds19.5% 
propranolol 
poly(SULV) chain 9 
)
he MD simulation at 7.41 ns. (b) Structure showing (R)-propranolol and poly(SULV)
Table 5
Molecular Micelle: atenolol hydrogen bonds formed in the (S)-atenolol pocket one
and four and (R)-atenolol pocket one and three MD simulations. Percent occupancies
of each pocket are also reported.
Acceptor atom Donor atom Percent occupancy
(S)-Atenolol pocket one (fi = 0.727)
MM chain 9: Val ACO2 (S)-Atenolol OH 76.96
MM chain 9: Val ACO2 (S)-Atenolol NH2+ 64.29
MM chain 18: Val ACO2 (S)-Atenolol CONH2 18.03
(S)-Atenolol OH MM chain 9: Val NH 8.21
MM chain 6: Val ACO2 (S)-Atenolol OH 6.87
MM chain 18: Val ACO2 (S)-Atenolol NH2+ 6.78
MM chain 9: Val ACO2 (S)-Atenolol NH2+ 6.37
(S)-Atenolol pocket four (fi = 0.273)
MM chain 4: Val ACO2 (S)-Atenolol OH 67.92
(S)-Atenolol CONH2 MM Chain 7: Leu NH 43.00
MM chain 4: Val ACO2 (S)-Atenolol NH2+ 40.86
MM chain 4: Val ACO2 (S)-Atenolol OH 19.88
MM chain 4: Val ACO2 (S)-Atenolol NH2+ 19.50
MM chain 17: O1 (S)-Atenolol CONH2 17.50
MM chain 4: Leu CO (S)-Atenolol NH2+ 16.54
MM chain 5: Val ACO2 (S)-Atenolol NH2+ 11.01
(R)-Atenolol pocket one (fi = 0.580)
MM chain 8: Leu ACO (R)-Atenolol NH2+ 34.06
MM chain 9: Val ACO2 (R)-Atenolol OH 33.11
MM chain 9: Val ACO2 (R)-Atenolol NH2+ 24.28
MM chain 9: Val ACO2 (R)-Atenolol NH2+ 18.69
(R)-Atenolol pocket three (fi = 0.419)
MM chain 7: Leu ACO (R)-Atenolol NH2+ 68.63
MM chain 11: Val ACO2- (R)-Atenolol OH 49.77
MM chain 11: Val ACO2 (R)-Atenolol OH 45.49
MM chain 11: Val ACO2 (R)-Atenolol NH2+ 41.31
MM chain 11: Val ACO2 (R)-Atenolol NH2+ 39.56
(R)-Atenolol OH MM chain 11: Val NH 13.48
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face, though, many intermolecular H-bonds could readily form
between the poly(SULV) dipeptide headgroup and atenolol
donor/acceptor atoms. Atenolol also contains an amide group para
to the chiral side chain that is not present in propranolol.
Therefore, atenolol’s larger number of potential H-bond donor
and acceptor atoms also likely facilitates more MM hydrogen bond
formation than in propranolol. Finally, recall that in the propra-
nolol MD simulations (S)-propranolol formed more H-bonds with
larger percent occupancies than (R)-propranolol. Table 5 shows
this is not the case with atenolol. Hydrogen bond formation for
both atenolol enantiomers were comparable in all four pockets
with respect to both the number of H-bonds formed and their per-
cent occupancies. This result is consistent with the atenolol enan-
tiomers having similar free energies of binding and with atenolol
showing weak chiral interactions with poly(SULV) in CE separa-
tions [28].
A further examination of the hydrogen bonds in Table 5 shows
that although the atenolol enantiomers form many hydrogen
bonds with the MM, very few of the hydrogen bonds involved
donor or acceptor atoms near the MM or atenolol chiral centers.
Of the 25 hydrogen bonds in Table 5, 17 were formed between a
valine carboxylate oxygen atom and a donor atom on the atenolol
alcohol or amine functional groups. These hydrogen bonds likely
place the atenolol enantiomers at or near the end of a MM surfac-
tant chain and away from the headgroup’s chiral atoms. Three ate-
nolol H-bonds in Table 5 formed between atoms of the MM and the
atenolol amide group para to the chiral side chain and an addi-
tional three H-bonds formed between the leucine carbonyl oxygen
and atenolol amine groups. These H-bonds also occur relatively far
from the chiral atoms. Only two atenolol hydrogen bonds bring
together chiral centers on the MM and ligand. A H-bond with a
13.48% occupancy formed between the Val NH of MM chain eleven
and the (R)-atenolol hydroxide group in pocket three and anotherH-bond with an occupancy of 8.21% formed between the (S)-ateno-
lol OH in pocket one and the Val NH of MM chain nine. Therefore,
even though the atenolol enantiomers formed many hydrogen
bonds with the MM, relatively few of those H-bonds brought
together the MM and atenolol chiral centers. This effect may also
contribute to the atenolol enantiomers having weak chiral interac-
tions with poly(SULV).4. Conclusions
The binding of propranolol and atenolol enantiomers to the
molecular micelle poly(SULV) were investigated with MD simula-
tions and NMR diffusion experiments. Binding free energy calcula-
tions showed that both propranolol enantiomers preferentially
bound to the sameMM binding site. Solvent accessible surface area
analyses and structures extracted from the MD simulations
showed that both propranolol enantiomers placed their aromatic
rings inside the MM core and placed their chiral side chains closer
to the micelle surface. Binding free energy calculations also
showed that (S)-propranolol interacted more favorably with
poly(SULV) than (R)-propranolol. This result was consistent with
CE and NMR results from the literature. The MD simulations sug-
gested the (S)-propranolol interactions with poly(SULV) were more
favorable in part because the (S) enantiomer experienced stronger
hydrogen-bonding interactions with poly(SULV) than (R)-propra-
nolol. In contrast, the atenolol enantiomers were both found to
experience favorable interactions with two different MM binding
pockets. The (R) and (S)-atenolol: MM binding free energies were
also found to be very similar to one another. This result was consis-
tent with NMR diffusion experiments showing (R)-atenolol and
(S)-atenolol diffused at the same rate in the presence of
poly(SULV). Finally, solvent accessible surface area analyses sug-
gested that atenolol’s hydrophilic character prevented the ligand
from interacting with the MM core. Instead, atenolol enantiomers
were found to bind primarily at or near the molecular micelle
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